The Global Metabolomics Services Market was valued at US$ 2.2 Bn in the year 2020 and is anticipated to grow US$ 5.02 Bn by 2027 at CAGR of 12.5% over the forecast years 2021-2027 due to growing integration of metabolomics data into clinical workflows such as growth of newborn genetic screening programs, advancements in noninvasive cancer screening and increasing interest towards targeted and personalized healthcare. Moreover, Increase in government role and funding in metabolomics and technological advances to facilitate metabolomic R&D are the major factors that are driving the growth of the global metabolomics services market over the forecast timeframe. This report studies global metabolomics services market dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Some of the major and important factors that will likely accelerate the growth of the metabolomics services market in the future include an increase in the number of patients suffering from neurological disorders, cancer, and cardiac diseases, increased growth of the healthcare industry globally, increased demand for personalised medicine, and an increase in the need for accurate disease diagnosis.